Targovax has announced that patents no CN108495934 and JP6974350 have been granted by the Chinese and Japanese Patent Offices, respectively.
The patents cover the use of ONCOS-102 in combination with chemotherapy in malignant mesothelioma.
“We are delighted that these patents have been granted, further strengthening Targovax’s intellectual property portfolio. The 30-month data from our ONCOS-102 trial in mesothelioma demonstrate very strong survival outcomes in the first-line setting, and this remains an area of high medical need. Securing these patents protects our innovative oncolytic immunotherapy platform and strengthens our future market position in the major Asian markets,” says Andreas Berg Storsve, VP Business Development and IP at Targovax.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system. In December 2021, the 30-month follow-up in the malignant pleural mesothelioma (MPM) trial showed 25.0 months median overall survival (mOS) for patients in first-line treatment with ONCOS-102 plus chemotherapy.
The US FDA granted ONCOS-102 Fast Track designation for MPM in February 2021 based on the pre-clinical and clinical data package. ONCOS-102 also has orphan drug designation for MPM with both the US FDA and the European Medicines Agency.